Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Industry: Medical Devices
Follow @stockchartsai on TwitterIn the past 30 trading days, DXCM has been trading in a range between $113.98 and $75.49 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
DXCM is trading between resistance at $123.81 about 4% to the upside and support at $114.51 -4% to the downside. If it can break above the resistance, it could have some more upside to the next line of resistance at $137.93, about a 16% move. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
DexCom Inc (DXCM) entered a Green zone 26 days ago on the AI powered stock chart. Wall Street analysts have a recent rating of 4.609, which is a Strong Buy. The current analyst target price is $137, which gives it a potential upside of 15.23 % from the recent price of 118.89. The stock is trading 17.38% (potential upside) below its 52 week high of $139.55 and 59.05 % (potential downside) above its 52 week low of $74.75 - based on the recent price.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers.
Is DexCom (DXCM) a Solid Growth Stock? 3 Reasons to Think "Yes" DexCom (DXCM) possesses solid growth attributes, which could help it handily outperform the market. Source: Zacks Investment Research Wed, 06 Dec 2023 14:17:11 -0500 Sentiment: Positive |
Dexcom G7 is Now the Most Accurate, Smallest, Easy-to-Use CGM Connected to the Tandem t:slim X2 Insulin Pump SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM, the world's most accurate1,2 CGM system. “There's a reason Dexcom is the undisputed leader in CGM connectivity and the clear choice. Source: Business Wire Wed, 06 Dec 2023 13:06:00 -0500 Sentiment: Neutral |
'Ten-bagger' stocks are the 'holy grail': Strategist As Wall Street weighs whether markets can sustain November's rally, investors are spotting opportunities. eToro Global Markets Strategist Ben Laidler joined Yahoo Finance Live to analyze high-growth "ten-bagger" stocks, which he calls "the holy grail for any investor. Source: Yahoo Finance Wed, 06 Dec 2023 12:00:27 -0500 Sentiment: Positive |
Dexcom G7, the Smallest, Most Accurate, Easy-to-Use CGM Now Connects to the Tandem t:slim X2 Insulin Pump SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM, the world's most accurate1,2 CGM system. “There's a reason Dexcom is the undisputed leader in CGM connectivity and the clear choice. Source: Business Wire Wed, 06 Dec 2023 08:40:00 -0500 Sentiment: Neutral |
Integra Gains From New Product Launches, Mounting Costs Ail Integra expands the international reach of the CUSA platform and registers DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America. Source: Zacks Investment Research Tue, 05 Dec 2023 09:46:08 -0500 Sentiment: Positive |
Stock Analyzed Each Night
Easily Upload Track Your Stocks
See Lists of Stocks Starting New Trends
The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.